Q BioMed Inc. (QBIO)

Market Cap	145.00
Revenue (ttm)	209.29K
Net Income (ttm)	-1.91M
Shares Out	145.09M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.0004
Previous Close	0.0004
Day's Range	0.0004 - 0.0005
52-Week Range	n/a
Beta	81.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Q BioMed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a part...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: QBIO

Financial Performance

In 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$3.49 million, -60.03% less than in 2021.